B-cell lymphoma 2 rs17757541 C>G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4301-4306

  Li, Qiong ^a   Yin, Jun ^b   Wang, Xu ^b   Wang, Li Ming ^b   Shi, Yi Jun ^b   Zheng, Liang ^c   Tang, Wei Feng ^b   Ding, Guo Wen ^b   Liu, Chao ^b   Liu, Rui Ping ^d   Gu, Hai Yong ^b   Sun, Jia Ming ^a   Chen, Suo Cheng ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

^d THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

BCL2; Gastric cardiac adenocarcinoma; Molecular epidemiology; Polymorphisms

Indexed keywords

PROTEIN BCL 2; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; CANCER STAGING; CARDIA; CASE CONTROL STUDY; CHINA; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HUMAN; MALE; PATHOLOGY; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STOMACH TUMOR;

ADENOCARCINOMA; AGED; CARDIA; CASE-CONTROL STUDIES; CHINA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; SMOKING; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885464448     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4301     Document Type: Article

References (24)

1. Alenzi FQ, Lotfy M, Wyse R (2010). Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev, 11, 271-80.
2. Chen K, Hu Z, Wang LE, et al (2007). Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 28, 2008-12.
3. Cheng J, Zhang H, Zhuang C, et al (2012). Peptidylarginine deiminase type 4 and methyl-CpG binding domain 4 polymorphisms in Chinese patients with rheumatoid arthritis. J Rheumatol, 39, 1159-65.
4. Cory S, Adams JM (2002). The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer, 2, 647-56.
5. Elmore S (2007). Apoptosis: a review of programmed cell death. Toxicol Pathol, 35, 495-516.
6. Enjuanes A, Benavente Y, Bosch F, et al (2008). Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res, 68, 10178-86.
7. Eun YG, Hong IK, Kim SK, et al (2011). A Polymorphism (rs1801018, Thr7Thr) of BCL2 is Associated with Papillary Thyroid Cancer in Korean Population. Clin Exp Otorhinolaryngol, 4, 149-54.
8. Giatromanolaki A, Koukourakis MI, Sivridis E, et al (2007). Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest, 37, 878-86.
9. Holler N, Tardivel A, Kovacsovics-Bankowski M, et al (2003). Two adjacent trimeric FAS ligands are required for FAS signaling and formation of a death-inducing signaling complex. Mol Cell Biol, 23, 1428-40.
10. Jain M, Kumar S, Lal P, et al (2007). Role of BCL2 (ala43thr), CCND1 (G870A). and FAS (A-670G). polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev, 31, 225-32.
11. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al (2000). Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest, 106, 1311-9.
12. Kroemer G (1997). The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med, 3, 614-20.
13. Lowe SW, Lin AW (2000). Apoptosis in cancer. Carcinogenesis, 21, 485-95.
14. Nagata S (1997). Apoptosis by death factor. Cell, 88, 355-65.
15. Nagata S (1999). FAS ligand-induced apoptosis. Annu Rev Genet, 33, 29-55.
16. Seto M, Jaeger U, Hockett RD, et al (1988). Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. Embo J, 7, 123-31.
17. Sun J, Li Q, Gu H, et al (2013). Interleukin 10 rs1800872 T>G Polymorphism was associated with an increased risk of esophageal cancer in a Chinese population. Asian Pacific J Cancer Prev, 14, 6213-7.
18. Wei J, Zheng L, Liu S, et al (2013). MiR-196a2 rs11614913 T>C polymorphism and risk of esophageal cancer in a Chinese population. Hum Immunol, doi:pii: S0198-8859(13)00169-9. 10.1016/j.humimm.2013.06.012 [Epub ahead of print].
19. Wu IC, Zhao Y, Zhai R, et al (2011). Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia, 13, 386-92.
20. Yarden Y, Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2, 127-37.
21. Yin J, Wang L, Shi Y, et al (2013). Interleukin 17A rs4711998 A>G polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Dis Esophagus, DOI: 10.1111/dote.12045.
22. Yu D, Jing T, Liu B, et al (1998). Overexpression of ERBB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell, 2, 581-91.
23. Zheng L, Yin J, Wang L, et al (2013). Interleukin 1B rs16944 G>A polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Clin Biochem, doi: 10.1016/j.clinbiochem.2013.05.050. [Epub ahead of print].
24. Zinkel S, Gross A, Yang E (2006). BCL2 family in DNA damage and cell cycle control. Cell Death Differ, 13, 1351-9.